{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:41:42Z","timestamp":1788370902956,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Tanta University Hospital"},{"DOI":"10.13039\/501100000866","name":"Cardiff University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000866","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Universidade Federal Paulista"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ijantimicag.2020.105925","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:44:29Z","timestamp":1582073069000},"page":"105925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5476-3949","authenticated-orcid":false,"given":"Lucas","family":"Tselepis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0875-3712","authenticated-orcid":false,"given":"Gareth W.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali F.","family":"Aboklaish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Widlake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana E.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Brem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Tyrrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ijantimicag.2020.105925_bib0001","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01076-18","article-title":"Past and Present Perspectives on \u03b2-lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105925_bib0002","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between \u03b2-lactamases and new \u03b2-lactamase inhibitors","volume":"17","author":"Bush","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105925_bib0003","unstructured":"Mushtaq S, Chaudhry A, Adkin R, Woodford N, Benedict N, Pypstra R et al. In vitro activity of diverse \u03b2-lactam\/AAI101 combinations vs. multidrug-resistant Gram-negative clinical strains. In: 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Abstract eP452. Basel, Switzerland: ESCMID."},{"key":"10.1016\/j.ijantimicag.2020.105925_bib0004","doi-asserted-by":"crossref","first-page":"e02260","DOI":"10.1128\/AAC.02260-16","article-title":"Cyclic Boronates Inhibit All Classes of \u03b2-Lactamases","volume":"61","author":"Cahill","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"17","key":"10.1016\/j.ijantimicag.2020.105925_bib0005","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1021\/jm400769b","article-title":"Assay Platform for Clinically Relevant Metallo-\u03b2-lactamases","volume":"56","author":"van Berkel","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105925_bib0006","doi-asserted-by":"crossref","first-page":"12406","DOI":"10.1038\/ncomms12406","article-title":"Structural basis of metallo-\u03b2-lactamase, serine-\u03b2-lactamase and penicillin-binding protein inhibition by cyclic boronates","volume":"7","author":"Brem","year":"2016","journal-title":"Nat Commun"},{"issue":"28","key":"10.1016\/j.ijantimicag.2020.105925_bib0007","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1039\/C7OB01514C","article-title":"13C-Carbamylation as a mechanistic probe for the inhibition of class D \u03b2-lactamases by avibactam and halide ions","volume":"15","author":"Lohans","year":"2017","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.ijantimicag.2020.105925_bib0008","doi-asserted-by":"crossref","first-page":"e02209","DOI":"10.1128\/AAC.02209-16","article-title":"In vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)","volume":"61","author":"Lob","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105925_bib0009","unstructured":"CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Tenth Edition. Wayne, USA: Clinical and Laboratory Standards Institute; 2015. M07-A10."},{"issue":"10","key":"10.1016\/j.ijantimicag.2020.105925_bib00010","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1128\/AAC.00897-16","article-title":"Interaction of Avibactam with Class B Metallo-\u03b2-lactamases","volume":"60","author":"Abboud","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105925_bib00011","doi-asserted-by":"crossref","first-page":"e02406","DOI":"10.1128\/AAC.02406-17","article-title":"Inactivation of the Pseudomonas-derived cephalosporinase-3 (PDC-3) by relebactam","volume":"62","author":"Barnes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105925_bib00012","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection: Clinical Implications of an Extended-Infusion Dosing Strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105925_bib00013","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.105925_bib00014","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/AAC.43.2.424","article-title":"Carbapenem Activities against Pseudomonas aeruginosa: Respective Contributions of OprD and Efflux Systems","volume":"43","author":"Kohler","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105925_bib00015","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.diagmicrobio.2019.05.001","article-title":"Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States- SMART 2017-2017","author":"Karlowsky","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105925_bib00016","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1128\/AAC.01947-13","article-title":"Efficacy of Humanized Carbapenem and Ceftazidime Regimens against Enterobacteriaceae Producing OXA-48 Carbapenemase in a Murine Infection Model","volume":"58","author":"Wiskirchen","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.105925_bib00017","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent \u03b2-Lacatm-\u03b2-Lactamase Inhibitor Combination","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105925_bib00018","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.diagmicrobio.2006.08.016","article-title":"Comparative activities of cefepime and piperacillin\/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype","volume":"57","author":"Sader","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105925_bib00019","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T19:32:11Z","timestamp":1735673531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920300686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0924857920300686"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105925","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105925"}}